Schedule 13D ownership disclosure
Keros Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 492327101
Event date: 2025-04-04
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ADAR1 Capital Management, LLCReported CIK 0001940272
Shares: 5,390,964.00 · Class: 13.29%
- ADAR1 Capital Management GP, LLC
Shares: 4,647,406.00 · Class: 11.46%
- Daniel Schneeberger
Shares: 5,390,964.00 · Class: 13.29%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-034310
- Form type
- SCHEDULE 13D
- Filer
- ADAR1 Capital Management, LLC
- CIK
- CIK 1940272
- Filed
- Apr 11, 2025
- Reporting period
- Apr 04, 2025
- Description
- Schedule 13D beneficial ownership